Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
MGF-1 Internal request: In response to the FDA approval of trilaciclib as an option to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. The panel requested the addition of a footnote on the MGF-1 stating, "Trilaciclib may be used as a prophylactic option to decrease the incidence of chemotherapy-induced myelosuppression when administered before (or G-CSF may be administered after) platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC)." **MGF-1** External Submission Submission from G1 Therapeutics (02/12/21) requesting the addition of trilaciclib as a footnote on **MGF-1** (Prior to First Chemotherapy Cycle) as a preferred option to decrease the incidence of chemotherapy induced myelosuppression from regimens containing platinum + etoposide +/- checkpoint inhibition; or a regimen containing topotecan.	Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include trilaciclib as a footnote on MGF-1. This is a category 2B recommendation. • See submission for references	12	3	3	14
MGF-3 Internal request: In response to the FDA approval of trilaciclib as an option to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. The panel requested the addition of a footnote on the MGF-3 stating, "Trilaciclib may be used as a prophylactic option to decrease the incidence of chemotherapy-induced myelosuppression when administered before (or G-CSF may be administered after) platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC)."	Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include trilaciclib as a footnote on MGF-3. This is a category 2B recommendation. • See submission for references	11	4	3	14

MGF-3 External Submission Submission from G1 Therapeutics (02/12/21) requesting the addition of trilaciclib as a footnote on **MGF-3** (Prior to Second and Subsequent Chemotherapy Cycles) as a preferred option to decrease the incidence of chemotherapy induced myelosuppression from regimens containing platinum + etoposide +/- checkpoint inhibition; or a regimen containing topotecan.					
MGF-A 1 of 5 and 2 of 5 Internal request: In response to the FDA approval of trilaciclib as an option to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. The panel requested the addition of a footnote on the MGF-A, 1 and 2 of 5, stating, "Trilaciclib may be used as a prophylactic option to decrease the incidence of chemotherapy-induced myelosuppression when administered before (or G-CSF may be administered after) platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC)." **MGF-A (1 of 5 and 2 of 5)** External Submission Submission from G1 Therapeutics (02/12/21) requesting the addition of trilaciclib as footnotes on **MGFA, 1&2/5** (Under Small Cell Lung Cancer regimens) as a preferred option to decrease the incidence of chemotherapy induced myelosuppression from regimens containing platinum + etoposide +/- checkpoint inhibition; or a regimen containing topotecan.	Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include trilaciclib as a footnote on MGF-A, 1 of 5 and 2 of 5. • See submission for references	14	1	3	14
ANEM-1 Internal request: In response to the FDA approval of trilaciclib as an option to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. The panel requested the addition of a footnote on the ANEM-1 stating, "Trilaciclib may be used as a prophylactic option to	Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include trilaciclib as a footnote on ANEM-1. Based on the review of the data in the noted references and the recent FDA approval, the panel consensus was to include trilaciclib as a footnote on MGF-1. This is a category 2B recommendation.	9	6	3	14

decrease the incidence of chemotherapy-induced myelosuppression when administered before (or G-CSF may be administered after) platinum/etoposide ± immune checkpoint inhibitor-containing regimens or a topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC)." **ANEM-1** External Submission Submission from G1 Therapeutics (02/12/21) requesting the addition of trilaciclib as a new pathway in **ANEM-1** as preferred option to decrease the incidence of chemotherapy induced myelosuppression from regimens containing platinum + etoposide +/- checkpoint inhibition; or a regimen containing topotecan.	• See submission for references				